Homepage
Author:
Crinetics Pharmaceuticals, Inc.
Posted Date:
May 7, 2026
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Crinetics Pharmaceuticals, Inc.
May 7, 2026
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Crinetics Pharmaceuticals, Inc.
April 27, 2026
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Crinetics Pharmaceuticals, Inc.
April 8, 2026
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals, Inc.
February 26, 2026
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
Crinetics Pharmaceuticals, Inc.
February 8, 2026
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Pharmaceuticals, Inc.
January 28, 2026
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals, Inc.
January 27, 2026
